In 22 patients with EGFR-mutated NSCLC after TKI failure, an open-label, single-arm, phase II trial assessed the immune cell profile and effectiveness of the modified regimen consisting of atezolizumab, bevacizumab (7.5 mg/kg), and chemotherapy [96]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.